Access to bone densitometry increases general practitioners' prescribing for osteoporosis in steroid treated patients

Annals of the Rheumatic Diseases

Volumn 63, Issue 2, 2004, Pages 183-186

  Dolan, A L ^a   Koshy, E ^a   Waker, M ^a   Goble, C M ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; PREDNISOLONE; STEROID; VITAMIN D;

ACCESS TO INFORMATION; ADULT; AGED; ARTICLE; BONE DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; DATA BASE; DENSITOMETRY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GENERAL PRACTITIONER; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; MALE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY; CROSS-SECTIONAL STUDIES; DIPHOSPHONATES; FEMALE; GLUCOCORTICOIDS; HUMANS; INFORMATION DISSEMINATION; MALE; MIDDLE AGED; OSTEOPOROSIS; PHYSICIAN'S PRACTICE PATTERNS; PREDNISOLONE;

EID: 1642580542     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.006130     Document Type: Article

References (18)

1. Silverman SL, Greenwald M, Klein RA, Drinkwater BL. Effect of bone density information on decisions about hormone replacement therapy: a randomized trial. Obstet Gynecol 1997;89:321-5.
2. Rubin SM, Cummings SR. Results of bone densitometry affect women's decisions about taking measures to prevent fractures. Ann Intern Med 1992;116(Pt 1):990-5.
3. Van Staa T, Leufkens HGM, Cooper C. The epidemiology of corticosteroid induced osteoporosis: a meta-analysis. Osteoporosis Int 2002;13:777-87.
4. Verstraeten A, Dequeker J. Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids. Ann Rheum Dis 1986;45:852-7.
5. Eastell R. Management of corticosteroid-induced osteoporosis. UK Consensus Group Meeting on Osteoporosis. J Intern Med 1995;237:439-47.
6. ACR Task Force. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. American College of Rheumatology Task Force on Osteoporosis Guidelines. Arthritis Rheum 1996;39:1791-801.
7. Gudbjornsson B, Juliusson UI, Gudjonsson FV. Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann Rheum Dis 2002;61:32-6.
8. Peat ID, Healy S, Reid DM, Ralston SH. Steroid induced osteoporosis: an opportunity for prevention? Ann Rheum Dis 1995;54:66-8.
9. Walsh LJ, Wong CA, Pringle M, Tattersfield AE. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 1996;313:344-6.
10. Grol R, Dalhuijsen J, Thomas S, Veld C, Rutten G, Mokkink H. Attributes of clinical guidelines that influence use of guidelines in general practice: observational study. BMJ 1998;317:858-61.
11. Tosteson AN, Rosenthal DI, Melton LJ 3rd, Weinstein MC. ost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med 1990;113:594-603.
12. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-40.
13. Luengo M, Picado C, Del Rio L, Guanabens N, Montserrat JM, Setoain J. Vertebral fractures in steroid dependant asthma and involutionary osteoporosis: a comparative study. Thorax 1991;46:803-6.
14. van Staa TP, Abenhaim L, Cooper C, Zhang B, Leufkens HG. Public health impact of adverse bone effects of oral corticosteroids. Br J Clin Pharmacol 2001;51:601-7.
15. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320-3.
16. Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporosis Int 2001;12:989-95.
17. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998;339:292-9.
18. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999;42:2309-18.